All times are listed in CEST (Central European Summer Time)
- Nicolas Girard (Paris, France)
- Noemi Reguart Aransay (Barcelona, Spain)
LBA47 - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
- Masahiro Tsuboi (Kashiwa, Japan)
Abstract
Background
Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits EGFR-TKI sensitising and EGFR T790M resistance mutations. It has efficacy in EGFRm NSCLC, including in central nervous system (CNS) metastases. In the Phase III ADAURA (NCT02511106) primary analysis adjuvant osimertinib showed a significant and clinically meaningful disease-free survival (DFS) benefit vs placebo (PBO) in pts with completely resected EGFRm (ex19del/L858R) NSCLC, ± adjuvant chemotherapy (CT): stage IIꟷIIIA DFS HR, 0.17; 99.06% CI, 0.11, 0.26; p<0.0001; stage IBꟷIIIA DFS HR, 0.20; 99.12% CI 0.14, 0.30; p<0.0001. We report updated exploratory analyses of DFS and recurrence patterns after 2 yrs added follow up.
Methods
Eligible pts (aged ≥18 yrs [≥20 in Japan/Taiwan], WHO PS 0/1, completely resected EGFRm stage IBꟷIIIA [AJCC 7th edition] NSCLC; adjuvant CT allowed) were randomised 1:1 to osimertinib 80 mg once daily or PBO for up to 3 yrs. Primary endpoint: investigator-assessed DFS in stage IIꟷIIIA. Secondary endpoints: DFS in stage IBꟷIIIA, overall survival and safety. Patterns of recurrence and CNS DFS were pre-specified exploratory endpoints. Data cut-off: 11 April 2022.
Results
Globally, 682 pts were randomised; osimertinib n=339, PBO n=343. In this updated analysis, in pts with stage IIꟷIIIA disease DFS HR was 0.23 (95% CI 0.18, 0.30; 242/470 events; 51% maturity); 3-yr DFS rate was 84% with osimertinib vs 34% with PBO. In the overall population (stage IBꟷIIIA) DFS HR was 0.27 (95% CI 0.21, 0.34; 305/682 events); 3-yr DFS rate was 85% with osimertinib vs 44% with PBO. In the osimertinib arm, fewer pts experienced local/regional and distant recurrence vs PBO. CNS DFS HR was 0.24 (95% CI 0.14, 0.42; 63/470 events) in stage IIꟷIIIA. The long-term safety profile remains consistent with the known profile of osimertinib.
Conclusions
With 2 yrs further follow-up, a continued DFS benefit was sustained with osimertinib vs PBO, consistent with the primary analysis. These mature data reinforce adjuvant osimertinib as standard of care for pts with EGFRm stage IB–IIIA NSCLC after complete tumour resection and adjuvant CT, when indicated.
Clinical trial identification
NCT02511106.
Editorial acknowledgement
The authors would like to acknowledge Rachel Gater, PhD, of Ashfield MedComms, an Inizio Company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
M. Tsuboi: Financial Interests, Advisory Role: AstraZeneca, Merck Sharp & Dohme, Novartis, Chugai Pharmaceutical Co. Ltd.; Financial Interests, Other, Research Support: Boehringer Ingelheim, Merck Sharp & Dohme, AstraZeneca, Ono Pharmaceuticals Co. Ltd., Bristol-Myers Squibb, Eli Lilly, Novartis, MIRXES Japan; Financial Interests, Invited Speaker: Johnson & Johnson, AstraZeneca, Eli Lilly, Chugai Pharmaceutical Co. Ltd., Taiho Pharma, Medtronic Japan Co., Ltd., Ono Pharmaceutical Co. Ltd., Merck Sharp & Dohme, Bristol-Myers Squibb, Teijin Pharma. Y. Wu: Financial Interests, Advisory Role: AstraZeneca, Boehringer Ingelheim, Novartis, Takeda; Financial Interests, Other, Research Support: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Hengrui, Roche; Financial Interests, Other, Honoraria: AstraZeneca, Beigen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche, Sanofi. C. Grohe: Financial Interests, Advisory Role: AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme; Financial Interests, Other, Travel Fees: Boehringer Ingelheim; Financial Interests, Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme. T. John: Financial Interests, Advisory Role: Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Ignyta, Novartis, Bayer. M. Majem Tarruella: Financial Interests, Advisory Role: Roche, AstraZeneca; Financial Interests, Other, Research Support: Bristol-Myers Squibb, Roche, AstraZeneca; Financial Interests, Other, Honoraria: Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Roche, Kyowa Kyrin, Pierre Fabre, Takeda, Bayer, Amgen Inc.. J. Wang: Financial Interests, Other, Honoraria: AstraZeneca, Beigne, Boehringer Ingelheim, Merck Sharp & Dohme. T. Kato: Financial Interests, Advisory Role: AstraZeneca, Amgen Inc., Chugai Pharmaceuticals Co., Ltd., Eli Lilly, Merck Serono, Merck Sharp & Dohme, Pfizer, Daiichi-Sankyo; Financial Interests, Speaker’s Bureau: AstraZeneca, Amgen Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly, Merck Serono, Merck Sharp & Dohme, Pfizer, Bristol-Myers Squibb, Novartis, Taiho Pharmaceutical, Boehringer Ingelheim, Roche; Financial Interests, Full or part-time Employment, Spouse: Eli Lilly; Financial Interests, Other, Research Support: AstraZeneca, Amgen Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly, Merck Serono, Merck Sharp & Dohme, Pfizer, Novartis, AbbieVie Inc., Regeneron. J.W. Goldman: Financial Interests, Other, Research Support: Advaxis, Array, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, G1 Therapeutics, Merck, Pfizer; Financial Interests, Other, Travel Fees: AstraZeneca; Financial Interests, Other, Honoraria: AstraZeneca, Bristol-Myers Squibb, Genentech, Pfizer. S. Kim: Financial Interests, Advisory Role: AstraZeneca, Boehringer Ingelheim, Novartis, Eli Lilly, Roche, Bristol-Myers Squibb; Financial Interests, Other, Research Support: AstraZeneca, Boehringer Ingelheim, Novartis, Eli Lilly, Yuhan. G. Mukhametshina: Financial Interests, Invited Speaker: Roche, AstraZeneca, EISAI; Financial Interests, Principal Investigator: Merck Sharp & Dohme, AstraZeneca. F. de Marinis: Financial Interests, Speaker’s Bureau: AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Takeda, Roche, MSD, X-Covery. F.A. Shepherd: Financial Interests, Stocks/Shares: AstraZeneca. D. Urban: Financial Interests, Advisory Role: AstraZeneca, Merck Sharp & Dohme; Financial Interests, Other, Honoraria: Roche, Merck Serono, Merck Sharp & Dohme, Takeda, AstraZeneca, Rhenium Oncotest, Ltd., Bristol-Myers Squibb. M. Stachowiak: Financial Interests, Full or part-time Employment: AstraZeneca. A.L. Bolanos: Financial Interests, Full or part-time Employment: AstraZeneca. X. Huang: Financial Interests, Full or part-time Employment: AstraZeneca; Financial Interests, Stocks/Shares: AstraZeneca. R.S. Herbst: Financial Interests, Advisory Board: AstraZeneca, Bolt Biotherapeutics, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, EMD Serono, I-Mab Biopharma, Immune-Onc Therapeutics, Inc., Immunocore, Ocean Biomedical, Inc., Revelar Biotherapeutics, Inc, Ribbon Therapeutics, Xencor, Inc; Financial Interests, Other, Consulting: Bristol-Myers Squibb, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc, Eli Lilly and Company, Genentech, Gilead, HiberCell, Inc., Janssen, Johnson and Johnson, Loxo Oncology, Mirati Therapeutics, NextCure, Novartis, Oncocyte Corp, Oncternal Therapeutics, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi; Financial Interests, Other, Research Support: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company; Financial Interests, Member of the Board of Directors: Immunocore, Junshi Pharmaceuticals; Financial Interests, Leadership Role: American Association for Cancer Research, International Association for the Study of Lung Cancer, Society for Immunotherapy of Cancer, Southwest Oncology Group. All other authors have declared no conflicts of interest.
LBA48 - Community-based mass screening with low-dose CT for lung cancer in Guangzhou
- Wenhua Liang (Guangzhou, China)
Abstract
Background
This study aimed to investigate an approach for lung cancer (LC) screening in the general population and develop a risk prediction model to improve risk assessment.
Methods
This project is a community-based mass screening with LDCT for the early detection of LC. Participants were enrolled and screened from 2015 to 2021. Eligible subjects were between 40 and 74 years of age among the residents from four communities in Guangzhou, while exclusion criteria were persons diagnosed with LC within the past 5 years. A questionnaire including detailed demographic data and health conditions was used. Binary logistic regression analysis was used to screen potential risk factors. A multivariate model was built based on the participant characteristics combined with carcinoembryonic antigen (CEA) at a cutoff of 3.9. Model discrimination was evaluated by the area under the curve (AUC).
Results
11,708 participants were screened, comprising 5,452 males and 6,256 females with a median age of 59 (IQR, 51-65) years. 189 (1.6%) LCs were diagnosed, among which 162 (85.7%) cases were in stage 0-I. Only 37 (19.6%) and 105 (55.6%) of diagnosed cases met the criteria per NCCN and Chinese screening guidelines, respectively. We found seven independent risk/protective factors for LC through multivariate adjustment (Table). Using these variables combined with CEA, the model presented an AUC of 0.71 (95%CI, 0.67-0.75), which was significantly higher than that of guidelines in NCCN (0.52, 95%CI 0.50-0.55) and China (0.62 95%CI 0.58-0.67), respectively. Stratified analysis by smoking and stages showed that the AUCs were higher among smokers (0.77, 95%CI 0.71-0.83) and stage I to IV LC (0.74, 95%CI 0.70-0.78, excluding MIA) than in non-smokers (0.69, 95%CI 0.64-0.74) and preinvasive diseases (AIS and MIA, 0.64, 95%CI 0.57-0.72), respectively.
Factor OR (95% CI) P value Personal cancer history 6.03 (4.02-9.02) ＜0.001 Exposure to silicon dioxide 5.22 (1.13-24.1) 0.034 Age 50-59 vs. 40-49 1.50 (0.82-2.76) 0.188 60-74 vs. 40-49 2.27 (1.26-4.09) 0.006 Food allergy 2.58 (1.33-5.02) 0.005 History of asthma 2.32 (1.31-4.13) 0.004 Family history of cancer Lung cancer 1.58 (1.04-2.40) 0.033 Other cancer 1.12 (0.77-1.64) 0.549 Allergy to temperature change 0.46 (0.28-0.77) 0.003
Conclusions
Mass screening with LDCT can identify early-stage LC in Guangzhou, and a risk prediction model based on participant characteristics combined with CEA improves LC risk assessment.
Clinical trial identification
NCT04938804.
Legal entity responsible for the study
The authors.
Funding
Guangzhou Municipal Party Committee and Municipal Government and Guangzhou Municipal Health Commission.
Disclosure
All authors have declared no conflicts of interest.
Invited Discussant LBA47 and LBA48
- Sanjay Popat (London, United Kingdom)
Q&A
- All Speakers (Lugano, Switzerland)
950O - Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial
- Idris Bahce (Amsterdam, Netherlands)
Abstract
Background
Neoadjuvant chemoradiotherapy (CRT) and surgery is a treatment option for patients with locally advanced stage non-small cell lung cancer (NSCLC) with limited mediastinal lymph node metastases. Pathological complete response (pCR) correlates with improved survival but is achieved in only approximately 30% of patients after CRT. Neo-adjuvant ipilimumab plus nivolumab (IPI-NIVO) can modulate the tumor microenvironment and may increase pathological responses. In a phase II study (INCREASE, EudraCT-Nr: 2019–003454-83), we studied the addition of IPI-NIVO to CRT.
Methods
This single-arm, prospective phase II trial aimed to enroll 26 evaluable patients with (borderline) resectable, T3-4N0–2 NSCLC. Enrolment commenced in Feb 2020. The primary end-point was pCR. A prespecified pCR threshold of 60% was tested against the historical rate of 30% with CRT alone. Co-primary end-points were safety and major pathological response (MPR), i.e., a residual viable tumor cells percentage of 10% or less. On day 1, platinum-doublet concurrent CRT, IPI 1 mg/kg IV and NIVO 360 mg flat dose IV were administered, followed by NIVO (360 mg flat dose IV) after 3 weeks. Radiotherapy consisted of 50-60 Gy in once-daily doses of 2 Gy, followed by a resection 6 weeks after the last dose of radiation.
Results
To date, pCR was achieved in 15 out of 24 (63%) patients who underwent surgery. The MPR rate was 79%. Toxicity of adding IPI-NIVO to CRT was acceptable (Grade 3-4 treatment-related adverse events 56%). No patient suffered delay in surgery due to the neoadjuvant treatment. No treatment-related deaths occurred. Neoadjuvant treatment enhanced the activation of CD4+ and CD8+ effector and memory subsets in peripheral blood and increased the expression of proliferation markers on CD8+ T cells in tumor-draining lymph nodes.
Conclusions
Our results indicate that adding IPI-NIVO to neoadjuvant CRT is safe, provides deep pathological responses and enhances T cell activation. These data support further research using this combination in locally advanced NSCLC planned for CRT followed by surgery, and support use of such strategies in patients presenting with an inoperable NSCLC.
Clinical trial identification
EudraCT 2019–003454-83; Netherlands Trial Register NL8435
Legal entity responsible for the study
Amsterdam UMC, Vrije Universiteit Medical Center, Department of Pulmonology
Funding
Bristol Myers Squibb (BMS)
Disclosure
I. Bahce: Financial Interests, Institutional, Advisory Board: BMS, Boehringer Ingelheim, AstraZeneca, Roche, Pfizer, Takeda, MSD; Financial Interests, Institutional, Research Grant: BMS, Boehringer Ingelheim, AstraZeneca. F.L. Schneiders: Financial Interests, Institutional, Research Grant: ViewRay. S. Hashemi: Financial Interests, Institutional, Advisory Board: AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, MSD, Novartis, Takeda, Xcovery, Loxo, Eli Lilly, Roche, Janssen, GSK, Roche. D. Oprea-Lager: Financial Interests, Institutional, Research Grant: Janssen. T.D. de Gruijl: Financial Interests, Institutional, Advisory Board: Lava Therapeutics, DCPrime, Macrophage Pharma; Financial Interests, Personal, Advisory Board: Partner Therapeutics; Financial Interests, Personal, Stocks/Shares: Lava Therapeutics; Financial Interests, Personal, Invited Speaker, Patent: Immunoglobulins binding human Vγ9Vδ2 T cell receptors; P31885NL00.: Lava Therapeutics; Financial Interests, Personal, Invited Speaker, Single domain antibodies targeting CD1d; P32016NL00; EP16715360.0-1412.: LAVA Therapeutics; Financial Interests, Personal, Invited Speaker, Patent: Novel bispecific antibodies for use in the treatment of haematological malignancies. WO/2020/060406, PCT/NL2019/050625.: LAVA Therapeutics; Financial Interests, Personal, Invited Speaker, Patent: Novel CD40 binding antibodies; WO/2020/159368; PCT/NL2020/050051: Lava Therapeutics; Financial Interests, Personal, Invited Speaker, Patent: Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase- (GSK3) and methods of killing aberrant cells. WO/2020/046130, PCT/NL2019/050562: Orca Therapeutics; Financial Interests, Institutional, Invited Speaker, Research funding from Idera Pharmaceuticals for an investigator-initiated clinical trial (INTRIM) on the intra-dermal administration of IMO-2125 CpG in early-stage melanoma;: Idera Pharmaceuticals; Financial Interests, Institutional, Research Grant, Contract research with Macrophage Pharma Inc. “Pre-clinical testing of the immune modulating effects of MPL-5821 in the tumor microenvironment”: Macrophage Pharma; Non-Financial Interests, Leadership Role, Member of the Board of Directors: SITC, Society for the Immunotherapy of Cancer (SITC); Non-Financial Interests, Advisory Role, Member of the grant review committee: MRA; Non-Financial Interests, Advisory Role, Member of their scientific grant reviewing committee: KWF; Non-Financial Interests, Institutional, Product Samples, Provision of Durvalumab for a clinical trial: AstraZeneca; Non-Financial Interests, Institutional, Product Samples, Provision of nivolumab for clinical trials: BMS; Non-Financial Interests, Institutional, Product Samples, Provision of Pembrolizumab for clinical trials: Merck; Non-Financial Interests, Member: AACR. T. Radonic: Financial Interests, Institutional, Advisory Board: Roche, Takeda. S. Senan: Financial Interests, Institutional, Advisory Board: Varian Medical Systems, ViewRay, AstraZeneca, BeiGene, Roche, MSD; Financial Interests, Institutional, Research Grant: Varian Medical Systems, ViewRay, AstraZeneca, BMS. All other authors have declared no conflicts of interest.
LBA49 - CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
- Edward B. Garon (Santa Monica, United States of America)
Abstract
Background
CAN is a high-affinity anti-IL–1β antibody that was superior to placebo (PBO) at preventing cardiac adverse events (AEs) in the CANTOS study. In an exploratory analysis of CANTOS, CAN was associated with significant reductions in NSCLC incidence and mortality, suggesting that CAN inhibition of the IL-1β pathway may have reduced the rate of progression, invasiveness, and metastatic spread of lung cancers undiagnosed at trial entry. Here, we show efficacy and safety of CAN as adjuvant therapy vs PBO in pts with completely resected NSCLC.
Methods
CANOPY-A (NCT03447769) is a Phase III study of adult pts with Stage II–IIIB (AJCC/UICC v8), completely resected NSCLC who had received adjuvant, cisplatin-based chemotherapy (CTx; if applicable) and thoracic radiotherapy (if applicable). Neoadjuvant CTx or chemoradiotherapy was not allowed. Pts were randomized 1:1 to receive CAN (200 mg) or PBO, subcutaneously, every 3 weeks for ≤18 cycles. Primary endpoint was disease-free survival (DFS); key secondary endpoint was overall survival (OS).
Results
At data cutoff (March 17, 2022), 1382 pts had been randomized to CAN (n=693) or PBO (n=689); baseline characteristics were generally balanced between arms. Median time from randomization to data cutoff was 18.9 months (mo; range 2.8–47.2); for DFS, there were 208 (30.0%) events with CAN and 218 (31.6%) with PBO. DFS was not significantly improved with CAN vs PBO (median 35.0 vs 29.7 mo; HR 0.94; 95% CI 0.78–1.14; one-sided p=0.258). Subgroup analyses (predefined based on demographics, baseline disease characteristics, and biomarkers) did not show any meaningful differences between the two arms for DFS. For OS, only to be formally tested if DFS was statistically significant, there were 44 (6.3%) events with CAN vs 56 (8.1%) with PBO. AEs were Grade ≥3 in 20.8% of pts in CAN arm vs 19.6% in PBO arm and AEs of any grade led to discontinuation in 4.3% of pts (CAN) vs 4.1% (PBO); on-treatment deaths occurred in 1.3% of pts (CAN) vs 2.3% (PBO).
Conclusions
CANOPY-A did not show a DFS benefit with CAN vs PBO after surgery and adjuvant CTx in pts with resected, Stage II–IIIB NSCLC. No new safety signals were identified with CAN treatment.
Clinical trial identification
CACZ885T2301/NCT03447769.
Editorial acknowledgement
Editorial assistance was provided by Alice Arcourt, PhD of Articulate Science Ltd, and was funded by Novartis Pharmaceuticals Corporation.
Legal entity responsible for the study
Novartis Pharmaceuticals Corporation.
Funding
Novartis Pharmaceuticals Corporation.
Disclosure
E.B. Garon: Financial Interests, Personal, Advisory Board: Novartis, Merck, BMS, EMD Serono, Regeneron, Sanofi, Natera, Shionogi, ABL Bio, Xilio, GSK, Boehringer Ingelheim, Eisai, Gilead, Eli Lilly, Personalis; Financial Interests, Institutional, Invited Speaker: Novartis, Merck, EMD Serono, Eli Lilly, Genetech, Iovance, Neon, Mirati, AstraZeneca, BMS, ABL Bio; Non-Financial Interests, Advisory Role, Scientific Advisory Board: Lungevity. S. Lu: Financial Interests, Institutional, Invited Speaker: Hansoh, AstraZeneca, Roche; Financial Interests, Research Grant: AstraZeneca, Hutchison, BMS, Heng Rui Beigene, Roche, Hansoh. Y. Goto: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Guardant Health Inc., Illumina, MSD, Novartis, Ono Pharmaceutical, Pfizer, Taiho, Johnson and Johnson, D3bio; Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, MSD, Merck, Novartis, Ono Pharmaceutical, Thermo Fischer, Pfizer, Taiho; Financial Interests, Institutional, Invited Speaker: Bristol Myers Squibb, DaiichiSankyo, Eli Lilly, Guardant Health, Preferred Network; Financial Interests, Personal and Institutional, Invited Speaker: Chugai, Pfizer, Novartis; Financial Interests, Institutional, Research Grant: Prefered Network. P.R. De Marchi: Financial Interests, Personal, Invited Speaker: Bristol-Myers Squibb, Pfizer, Roche, Boheringer Igelheim, AstraZeneca, Bayer, MSD, Janssen, Amgen, Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Sanofi, Roche, Janssen, Lilly; Financial Interests, Institutional, Invited Speaker: Bristol-Myers Squibb, Roche, Pfizer, Boheringer Ingelheim, Xcorery, MSD, IRX, AstraZeneca, Lilly. L. Paz-Ares: Financial Interests, Personal, Advisory Board, Speaker fees: Roche, MSD, BMS, AZ, Lilly, PharmaMar, Beigene, Daichii, Medscape, PER; Financial Interests, Personal, Advisory Board: Merck Serono, Pfizer, Bayer, Amgen, Janssen, GSK, Novartis, Takeda, Sanofi, Mirati; Financial Interests, Personal, Other, Board member: Genomica, Altum sequencing; Financial Interests, Institutional, Invited Speaker: Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme corp, BMS, Janssen-Cilag international NV, NOvartis, Roche, Sanofi, Tesaro, Alkermes, Lilly, Takeda, Pfizer, PharmaMar; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Other, Member: AACR, ASCO, ESMO; Financial Interests, Other, Foundation Board Member: AECC; Financial Interests, Other, President.ASEICA( Spanish Association of Cancer Research ): ASEICA; Financial Interests, Other, Foundation president: ONCOSUR; Financial Interests, Other, member: Small Lung Cancer Group. M. Thomas: Financial Interests, Personal, Advisory Board: Sanofi, Lilly, BMS, MSD, Roche, Boehringer, Janssen, AstraZeneca, Amgen, Novartis; Financial Interests, Personal, Invited Speaker: Sanofi, Lilly, MSD, Roche, GSK, Pfizer, Janssen, AstraZeneca, Amgen, Novartis; Financial Interests, Institutional, Advisory Board: Takeda; Financial Interests, Institutional, Invited Speaker: Takeda; Financial Interests, Institutional, Funding: Roche, Takeda, BMS, AstraZeneca, Amgen. J.C. Yang: Financial Interests, Institutional, Advisory Board: AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Amgen, Novartis, Bayer, GSK, Takeda Oncology, Puma Pharmaceuticals, Ono Pharmaceuticals, Merck Serono, MSD, Pfizer, Eli Lilly, Roche/Genentech, Janssen; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Boehringer Ingelheim, Novartis, AstraZeneca, MSD, Ipsen, Takeda Oncology; Financial Interests, Personal, Advisory Board: Yuhan Pharmaceuticals; Financial Interests, Invited Speaker: Dizal Pharmaceutical, Novartis, Numab, Merck, Daiichi Sankyo, Eli Lilly, Bayer, Janssen; Non-Financial Interests, Leadership Role, Board of Director: IASLC; Non-Financial Interests, Member: ASCO. A. Ardizzoni: Financial Interests, Personal, Invited Speaker, Occasional fees for advisory board participation and lectures: BMS; Financial Interests, Personal, Advisory Board, Occasional fees for advisory board participation: MSD, Takeda, Lilly, Bayer; Financial Interests, Personal, Advisory Board, Occasional fee for advisory board participation: Roche; Financial Interests, Personal, Advisory Board, Occasional fees for advisory board participation and lectures: AstraZeneca; Financial Interests, Institutional, Invited Speaker, Financial support to my University for covering 50% costs of a no-profit accademic clinical trial: Ipsen. F. Barlesi: Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd.. S. Khanna: Financial Interests, Personal, Full or part-time Employment: Novartis Pharma S.A.S. C. Bossen: Financial Interests, Institutional, Full or part-time Employment: Novartis Pharma AG. M. Carbini: Financial Interests, Institutional, Full or part-time Employment, Clinical Development Medical Director-Lung: Novartis; Financial Interests, Institutional, Stocks/Shares: Novartis. A. Yovine: Financial Interests, Institutional, Full or part-time Employment: Novartis. B.C. Cho: Financial Interests, Personal, Other, Consulting role: Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Medpacto, Blueprint medicines; Financial Interests, Personal, Advisory Board: Kanaph Therapeutic Inc, Brigebio therapeutics, Cyrus therapeutics, Guardant Health, Joseah BIO; Financial Interests, Personal, Invited Speaker: Gencurix Inc, Interpark Bio Convergence Corp.; Financial Interests, Personal, Stocks/Shares: TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, Kanaph Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp; Financial Interests, Personal, Royalties: Champions Oncology; Financial Interests, Institutional, Research Grant: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, AbbVie, Medpacto, GIInnovation, Eli Lilly, Blueprint medicines, Interpark Bio Convergence Corp.; Other, Founder: DAAN Biotherapeutics. All other authors have declared no conflicts of interest.
Invited Discussant 950O and LBA49
- Noemi Reguart Aransay (Barcelona, Spain)
Q&A
- All Speakers (Lugano, Switzerland)